BUY IPCA Laboratories Limited — Nuvama Wealth
byNuvama WealthHorizon: NA (inferred 1 year)17 Aug 2026via ET Now (Live)
Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.
AI Assessment
Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.
Long-term trend bullish — 200-day average rising over the past quarter
Technicals · trend·4 Sept · 2d ago
Elara initiates coverage on Alkem, Eris, IPCA and Mankind. Check ratings and targets
NewsEt-Markets·28 Aug · 1w ago
Lyka Labs standalone profit surges 159% in Q1FY27 on export strength
NewsGoogle News·23 Aug · 2w ago
Ipca Laboratories: Motilal Oswal வழங்கும் ₹2,060 டார்கெட் விலை!
NewsGoogle News·18 Aug · 3w ago
Ipca Laboratories: Motilal Oswal Sets Rs 2,060 Target After Q1 Beat
NewsGoogle News·18 Aug · 3w ago
Ipca Laboratories shareholders approve all resolutions at 76th AGM
NewsGoogle News·14 Aug · 3w ago
IPCA Laboratories Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
NSE · Outcome of Board Meeting·13 Aug · 3w ago
Standalone and Consolidated Unaudited Financial Results for Q1FY27
BSE · Board Meeting·13 Aug · 3w ago
Lyka Labs Limited Passes All Five Resolutions at 47th Annual General Meeting
NewsGoogle News·11 Aug · 4w ago
Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

